BioWin Day’s Post

Transcript

I think it was a very interesting workshop. I think one of the key messages is that you never have to give up. So if you feel that the doors are closed with the investors, try to generate new data, have a story ready and go back and update the investors on the on the data. From my own experience, I know that at the end there is the right timing, there is right story, there is the interest and then all these. Aspects come together, so you come with good signs, a good team and a good story and at the end you will be successful. Well, it all begins with good science. So a good data pack with good data with a good plan that is allowing you to create value with clinical trials or goods in vivo data set is always the good start of an investment firm. Equally important I would always say is a good management team. So the people that can translate that science into a product, people that have the experience to do so or that can surround themselves if they're first time CEO surround themselves with good team of people that have done this. Already once or twice and finally it's always important to have a good syndicate of investors. Make sure that you have like minded investors who share the same strategy and it can take a lot of time to discuss and agree on that strategy. But it's very important because it avoids problems or any discussions linked to discussions once the company hits a setback or turn around. If you have pre discussed a number of scenarios before the investment, you will have those discussions on a much easier basis than when you didn't do that. So we actually recently saw that in the US the IPO market is opening again. So in the shares are stabilizing, the market volatility is stabilizing. So now we first need some pioneers to IPO in the other sectors than biotech, which we see now happening in the US hopefully in the next couple of months. This is also dripping over into into Europe where we'll probably first see some big air IPO's in the non tech or the non biotech sector. We're then hopefully in a couple of months later the biotech sector will will follow. So let's hope I'm a, I'm a, I'm an optimist, but let's say that by mid 2024 we maybe see the first signs of recovery for the biotech IPOs in Mira. Let's see if there's an IPO is a real opportunity in term of financing the clinical development plan of of narrative And finally the clinical development plan conditions the size of the IPO and it's why for us is an evidence that based on our markets and base also all the money request to spread our clinical development plan. Yes, the US IPO that's the best place in view to raise enough money to support our developments based on the money required. A large number of clinical trials in mainly in the US because our market is in US, yes, it's clear that US NASDAQ IPO, that's the place to be for us, for us.